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pluripotency is key for the development of biomedical applications of stem cells. Nanog plays an important role in early
development and is essential to induce natural pluripotency in embryonic stem cells (ESCs). Inducible gain-of-function systems
allowing a precise control over time and dosage of Nanog activity would be highly desirable to study its vital role in the
establishment and maintenance of pluripotency at molecular level. Here we engineered a recombinant cell permeable version
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Embryonic stem cells (ESCs) differ from somatic cells by
indefinite symmetrical cell divisions and retaining the ability
to differentiate into all cell types of the organism (termed
pluripotency). A comprehensive understanding of the underly-
ing molecular network of cellular factors (Loh et al., 2006),
extrinsic stimuli (Smith et al., 1988; Williams et al., 1988),
intracellular signaling pathways (Ermakov et al., 2012), cell
cycle regulation (Coronado et al., 2013) and microenviron-
ment (Fernandes et al., 2010), establishing and maintaining
pluripotency and controlling differentiation is key for the
development of biomedical applications of stem cells. Stimula-
tion by extrinsic factors has been reported to be essential for
self-renewal and pluripotency. The cytokine leukemia inhibito-
ry factor (LIF) is required for the culture of mouse ESCs in
serum-supplementedmedia (Smith et al., 1988; Williams et al.,
1988) activating the signal transducer and activator of
transcription-3 (STAT3). Withdrawal of LIF from the culture
mediumcan be partially compensated by inducible activation of
STAT3 as has been shown by employing a tamoxifen-inducible
STAT3-estrogen-receptor fusion protein (Matsuda et al.,
1999). LIF in concert with BMP4 has been demonstrated to
sustain pluripotency and self-renewal in the absence of serum
(Ying et al., 2003). Both extrinsic signals are integrated into
the transcriptional machinery maintaining stem cell proper-
ties via intrinsic messenger molecules. Overexpression of the
homeodomain transcription factor Nanog is sufficient to
maintain mouse ESC self-renewal independent of LIF and
feeder cells, suggesting a role for Nanog as an important
downstream regulator of extracellular signals (Chambers et
al., 2003; Mitsui et al., 2003). Although Nanog plays a vital role
in the establishment of pluripotency its particular role at
molecular level is still not fully understood.
Inducible gain-of-function systems allowing a precise
control over time and dosage of Nanog activity would be
highly desirable to study stemness and nuclear reprogramming
pathways. Recently, biologically active recombinant cell-
permeant versions of the pluripotency factors Oct4, Sox2,
Klf4 and c-Myc proteins have been reported by us and other
groups (Bosnali & Edenhofer, 2008; Kim et al., 2009; Zhang
et al., 2012; Zhou et al., 2009). Protein transduction involves
the generation of recombinant fusion proteins consisting of
the protein-of-interest and a so-called cell penetrating peptide
(CPP), e.g. derived from the trans-activator of transcription
(TAT) protein encoded by Tat gene in HIV or arginine-rich
peptides (Bosnali & Edenhofer, 2008; Kim et al., 2009; Zhang
et al., 2012; Zhou et al., 2009). Several reports demonstrate
the expression and purification of recombinant Nanog protein
from mouse, human, luxi cattle and chicken, either as an
authentic full-length protein (Ha et al., 2009; Hu et al., 2012;
Loh et al., 2006; Yang et al., 2009; Yang et al., 2011; Yu et al.,
2013; Zhang et al., 2012) or as a truncated version (Jauch
et al., 2008). Although these studies report that recombinant
Nanog is able to bind to DNA (Ha et al., 2009; Jauch et al.,
2008; Loh et al., 2006; Yang et al., 2009; Yang et al., 2011),
the overall biological activity remained unclear.
In this study we demonstrate the expression and purifica-
tion of recombinant cell-permeant Nanog in fusion with the
TAT. Nanog-TAT translocates to both, cytoplasm and nucleus,
and is stable under cell culture conditions. Nanog-TAT promotes
mouse ESC proliferation, self-renewal, inhibits endodermalspecification in a Stat3-independent manner and promotes
pluripotency in the absence of LIF. Our results demonstrate
that Nanog protein transduction is a powerful method to
study molecular mechanisms underlying pluripotency without
genetic manipulation.Materials and methods
Cell culture
Mouse ESCs were cultured on gelatin-coated dishes in high
glucose DMEM (Gibco) with 15% FCS, 1% non-essential amino
acids, 1 mM sodium pyruvate, 2 mM L-glutamine and
100 μM β-mercaptoethanol and 1000 U/ml LIF (Chemicon)
or Advanced DMEM (Gibco) with 5% Fetal calf serum (FCS),
2 mM L-glutamine, 100 μMβ-mercaptoethanol and 1000 U/ml
LIF. For standardization, differentiated cells were counter-
selected from Oct4-GiP ESCs (Oct4-GiP; (Ying et al., 2002)) by
adding 1 μg/ml puromycin for at least 1 week before an
experiment. Cells were passaged every 2–4 days using TrpLE
(Trypsin-like Enzyme, Invitrogen) for dissociation. For aggre-
gation experiments 2 × 10
5
Oct4-GiP ESCs were transferred
into Petri dishes (Nunc). In all experiments medium was
changed daily. The LIF inhibitor hLIF-05 (Vernallis et al.,
1997) was produced in COS-7 cells electroporated with the
hLIF-05 expression plasmid and the supernatant was tested
for its ability to block LIF signaling (Fig. S1). In all LIF-free
experiments the inhibitor was used at a concentration that
blocked at least 20 U/ml LIF. CV1 fibroblasts were cultured
in Dulbecco's modified Eagle medium (DMEM, Invitrogen)
containing 10% fetal calf serum, 1% non-essential amino acids,
1% sodium pyruvate and 100 U/ml penicillin and 0.1 mg/ml
streptomycin.Plasmid construction and preparation of recombinant
fusion proteins
For Nanog-TAT, PCR fragments encompassing the open
reading frames for NLS-Nanog-TAT-H6 flanked by NcoI-XhoI
sites were inserted into the NcoI-XhoI sites of pTriEx1.1
(Novagen). The TAT-Nanog plasmid (pTriEx-HTNNanog)
was generated by insertion of PCR amplified Nanog cDNA
flanked by a HindIII and a nuclear localization sequence
(NLS) (N-terminal) and a XhoI site (C-terminal) into
HindIII and XhoI sites of pTriEx-HTNCre. For bacterial
over-expression, overnight cultures (LB containing 0.5%
glucose and 50 μg/ml Carbenicillin) were inoculated with
freshly transformed BL21 (DE3) GOLD cells (Stratagene)
and cultured at 30°C. Expression cultures (TB containing
0.5% glucose and 100 μg/ml Ampicillin) were grown at
37°C and induced at an OD600 of 1.5 with 0.5 mM isopropyl-
β-D-thiogalactopyranoside (IPTG) for 1 h. Pellets were
resuspended in lysis buffer (2 mM imidazole, 500 mM NaCl,
50 mM Na2HPO4, 5 mM Tris, pH 7.8) and lysozyme (Sigma)
and benzonase (Novagen) was sequentially added, each for
20 min at 4°C. After a centrifugation step the supernatant
was incubated for 1 h with 1 ml Ni-NTA slurry (Qiagen) per
liter initial culture. The resin was packed in a gravity
column, washed (5 mM imidazole, 500 mM NaCl, 50 mM
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(250 mM imidazole, 500 mM NaCl, 50 mM Na2HPO4, 5 mM Tris,
pH 7.8) with 8 bed volumes. Eluted fractions were successively
dialyzed against PBS followed by non-supplemented KnockOut-
DMEM (Gibco).
Nanog protein transduction
Culture media for transduction experiments were prepared
by mixing Nanog dialysates 1:1 with double supplemented
medium (AdvDMEM additionally supplemented with 2% FCS, 1%
insulin-transferrin-selenium (ITS) (Invitrogen), 1% non-essential
amino acids, 4 mM glutamine and 200 μM β-mercaptoethanol).
The mixture was incubated in a water bath for 2 h at 37°C
and cleared from precipitations by centrifugation and sterile
filtration. FCS was then added to a final concentration of
5%. After this treatment the concentration for Nanog-TAT is
approximately 100 nM. Final Nanog-TAT concentration in FCS
containing medium was determined via dot blot analysis with
Nanog-TAT dialysates serving as standard.
EB and teratoma formation
Oct4-GiP ESCs were cultured for 12 passages without LIF in
the presence of Nanog-TAT and the LIF-Inhibitor hLIF-05.
Control cells without Nanog-TAT differentiatedwithin the first
4 passages and stopped to proliferate. To remove differenti-
ated cells from Nanog-TAT cultures 1 μg/ml puromycin was
added 2 days before cell aggregation. The suspension cultures
were kept for 2 weeks in Petri-dishes with LIF-free ES
medium. For teratoma formation Nanog-TAT cultures were
kept for 11 passageswithout LIF. LIF was then added to expand
the cells and cells were splitted (1:4 or 1:8) every 2–4 days
when they reached confluency of around 70–80% for 5
passages. 1 × 106 of these expanded cells was then injected
into a severe combined immunodeficiency (SCID)-beige
mouse. After 8 weeks, the developed teratoma was isolated
and subjected to histological examination with hematoxylin
and eosin staining.
Electrophoretic mobility shift assay (EMSA)
Binding of 100 ng recombinant Nanog-TAT protein and 0.5 ng
biotinylated oligonucleotides was performed in 20 μl binding
buffer (10 mM Tris, 50 mM KCl, 1 mM DTT, 2.5% glycerol,
5 mMMgCl2, 1 μg poly(dI-dC), 0.05% NP-40). Binding reactions
were separated by native PAGE, subsequently blotted on a
positively charged nylon membrane (Roche) and analyzed with
the LightShift Chemiluminescent EMSA kit (Pierce) according to
manufacturer's specifications. Signals were detected with the
CCD camera of a ChemiDoc XRS documentation system (Biorad).
Oligo sequences:5′-TCGACACCCTTCGCCGATTAAGTACTTAAG (sense)
5′-TCGACTTAAGTACTTAATCGGCGAAGGGTG (antisense)
RT-PCR
RNA from aggregates or somatic cells was isolated with the SV
Total RNA Isolation System (Promega) or Trizol (Invitrogen),respectively, and reverse-transcribed with M-MLV Reverse
Transcriptase, RNase H Minus, Point Mutant (Promega). PCR
reactions were performed using GoTaq (Promega).
Oct4-F: 5′-AGTGGAAAGCAACTCAGAGGG
Oct4-R: 5′-GGTTCTCATTGTTGTCGGCTT
Nanog-F: 5′-AGGGTCTGCTACTGAGATGCTCTG
Nanog-R: 5′-CAACCACTGGTTTTTCTGCCACCG
Rex-1-F: 5′-CGTGTAACATACACCATCCG
Rex-1-R: 5′-GAAATCCTCTTCCAGAATGG
GATA6-F: 5′-GCAATGCATGCGGTCTCTAC
GATA6-R: 5′-CTCTTGGTAGCACCAGCTCA
TTR-F: 5′-CTCACCACAGATGAGAAG
TTR-R-: 5′-GGCTGAGTCTCTCAATTC
GAPDH-F: 5′-ACGACCCCTTCATTGACCTCAACT
GAPDH-R: 5′-ATATTTCTCGTGGTTCACACCCAT
Flow cytometry analysis
Flow cytometry analysis was performed with a FACSCalibur
(BD Biosciences) and data was analyzed using CellQuest
Acqusition software (BD Biosciences) as described in the
FACSCalibur System User Guide.
Immunohistochemistry and staining
For immunostaining of embryoid bodies (EBs) paraffin-
embedded slices were stained in a DakoCytomation Autostainer
(DakoCytomation) according to the manufacturer's instructions
using the following antibodies: mouse anti-pan cytokeratin
(CK, Chemicon), mouse anti-α-desmin and rabbit anti-human
α-1-fetoprotein (AFP, both from DakoCytomation). For visual-
ization the EnVision System (DakoCytomation) with horseradish-
coupled secondary antibodies against mouse and rabbit was
used and diaminobenzidine (DAB) as chromogenic substrate.
For immunostaining cells were fixed with 4% paraformaldehyde
for 10 minutes at room temperature. Cells were successively
treated with the following antibodies: anti-SSEA1 (mouse IgM,
1:80; Hybridoma Bank), biotinylated anti-mouse IgM (1:200,
DAKO) in combination with FITC-Avidin, anti-Oct4 (rabbit IgG,
1:400, Santa Cruz Biotechnology, Inc.), Cy3 goat anti-rabbit
IgG (1:400, Jackson Immuno Research). Cells were also stained
with Sox2 (mouse mAb, 1:100, MAB2018; R&D Systems), Rex-1
(Rabbit pAb, 1:500; ab28141; Abcam) and FoxD3 (mouse mAb,
1:500; ab107248; Abcam). Secondary Alexa488- or Alexa555-
labeled antibodies (1:1000; Life technologies, Carlsbad, CA)
were used to detect and visualize the primary antibodies.
For intracellular staining, 0.1% Triton was added to the
antibody solutions. DAPI was used for nuclear counterstaining.
Alkaline phosphatase (AP) activity was detected with the
Alkaline Phosphatase Substrate Kit III (Vector Laboratories,
Inc.) or the Alkaline Phosphatase Detection Kit (Chemicon).
Western blotting
SDS-PAGE separated protein samples were blotted on a
nitrocellulose membrane. Immunoblots against total Stat3
and Tyrosine 705 phosphorylated (pY-705) Stat3 were
performed with rabbit anti-Stat3 (9132; Cell Signaling
Technology) and rabbit anti-Phospho-Stat3 (Tyr705) (9131;
Cell Signaling Technology), respectively. As secondary antibody
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Technology). Detection was carried out with SuperSignal West
Pico Chemiluminescent Substrate (PIERCE).
Results
Purified recombinant Nanog-TAT specifically binds to
consensus sequence
To achieve induction of Nanog activity by direct protein
delivery rather than genetic manipulation, we intended to
generate cell-permeable biologically active Nanog protein.
Based on our previous experience with the cell-permeable
Cre recombinase H6-TAT-NLS-Cre (Peitz et al., 2002), we
decided to construct a fusion gene of Nanog together with
the highly basic transduction peptide TAT derived from the
HIV transactivator of transcription. Using the same approach,
we have generated transducible versions of Oct4 and Sox2
proteins (Bosnali & Edenhofer, 2008), and demonstrated that
protein transduction could replace invasive viral transduction
approach to generate induced puripotent stem (iPS) (Thier et
al., 2010; Thier et al., 2012a) and induced neural stem (iNS)
(Thier et al., 2012b) cells. To identify a recombinant Nanog
version with superior biochemical properties, we screened
several variants of Nanog fusion proteins with different tag
(NLS, TAT, His) combinations at both N- and C-terminal ends of
Nanog (data not shown). Out of those variants, we determined
NLS-Nanog-TAT-His (designated as Nanog-TAT hereafter)
exhibiting the best combination of yield, purity, stability at
cell culture conditions and its ability to translocate to the
nucleus, and was therefore chosen for further analysis.
Nanog-TAT is soluble under cell culture conditions and is
able to translocate to both, cytoplasm and nucleus, of more
than 95% of cultured mammalian cells when added to the cell
culture media (Fig. S2 A). Immunostaining of Nanog-TAT
treated mammalian cells revealed the presence of Nanog
protein in the nucleus (Fig. S2 A). However, it also showed that
cellular uptake of Nanog-TAT results in persistent endosomal
entrapment in the periphery of the nucleus of all cells (Fig. S2
A). Nanog-TAT concentration reduced to approximately 50%
within 48 h in cell-free conditions and 24 h when co-incubated
with cultured cells (Fig. S2 B). Based on these observations we
decided to replace Nanog-TAT-supplemented media every
24 h in cell culture assays.
To assess the biological activity of Nanog-TAT in vitro we
performed an EMSA employing an oligonucleotide containing
a Nanog binding DNA sequence (Pan & Pei, 2005). Specificity
of the binding was analyzed by addition of excess competitor,
i.e. unlabeled DNA. Recombinant Nanog-TAT protein induced
a shift of the labeled DNA that could be blocked by unlabeled
oligonucleotides (Fig. 1A) confirming the specificity of the
binding of Nanog-TAT to the DNA.
Nanog-TATpromotes ESCproliferation and self-renewal
To analyze the functionality of Nanog-TAT in ESC prolifera-
tion, we used 3 different murine ESC lines namely, Bruce-4
(C57BL/6), Oct4-GiP (129/MF1) and RF8 (129/TerSv) and
cultured them in the absence of LIF but in the absence or
presence of Nanog-TAT for at least 14 to 17 days. To rule out
stimulation from endogenous LIF, we employed the LIFinhibitor hLIF-05 which has been reported to block the
activity of all known LIF receptor ligands (Chambers et al.,
2003; Vernallis et al., 1997) (Fig. S1). At each passage, the
cells were counted and the cumulative numbers of cells
were determined. Cells were passaged at the ratio 1:4 or
1:8 when they reached the confluency of around 70–80%.
After removal of LIF, untreated cells rapidly differentiated
and ceased to proliferate within 2–4 passages. In contrast,
Nanog-TAT-treated cells kept proliferating (Figs. 1 B, C, D) for
more than 20 passages (data not shown). Withdrawal of
Nanog-TAT from these Nanog-TAT-treated LIF-free cultured
ESCs resulted in complete differentiation within few passages.
Moreover, we observed an enhanced proliferation upon com-
bined application of LIF and Nanog-TAT in Oct4-GiP ESCs
(Fig. 1E).
We next examined the biological activity of Nanog-TAT on
ESCs to modulate ESC self-renewal. For this, we cultured
Bruce-4 (C57BL/6) ESCs in the absence of LIF on gelatinized
plates. Under these conditions control cells rapidly differ-
entiated within few days. We found no undifferentiated
colony after 3 days of LIF-withdrawal as judged by mor-
phology (Fig. 2A). Even in the presence of LIF we observed a
large fraction of spontaneously differentiated cells pre-
dominantly adopting a primitive endoderm-like morphology
(Fig. 2A). In contrast, Nanog-TAT-treated cells exhibited
significantly reduced differentiation in the absence of LIF.
Moreover, both LIF andNanog-TAT nearly completely inhibited
spontaneous differentiation and induced growth of colonies
exhibiting morphologies resembling ESCs cultured on feeder
layers (Fig. 2A). AP staining after 3 days further confirmed
that Nanog-TAT-treated cultures maintained an undifferenti-
ated state of these cells (Fig. 2B). In order to quantify the
effect of Nanog-TAT on murine ESCs AP stained cells were
classified into three categories. The first category, termed
‘undifferentiated’, encompassed compact colonies with sharp
edges strongly staining for AP. The second category comprised
partially compact colonies, which lost the sharp edges and
stained partially for AP. This category was named ‘mixed’. The
third category was named ‘differentiated’ and contained
colonies, which already lost the compact, three-dimensional
structure and did not stain for AP. In the presence of LIF the
amount of undifferentiated ESC colonies increases from 60%
to over 95%. In the presence of LIF, differentiation of ESCs is
inhibited. In the presence of Nanog-TAT, 25% ofmixed colonies
are still observed, whereas the complete absence of Nanog-
TAT leads to full differentiation (Fig. 2C). We observed similar
observations with Oct4-GiP ESCs when these cells were
cultured either in the presence or absence of the cytokine
LIF togetherwith 100 nMof Nanog-TAT (Fig. 2D).When exposed
to both, Nanog-TAT and LIF, both ESC lines formed tightly
compacted and loosely attached colonies and the cultures were
nearly devoid of any differentiated colonies (Figs. 2 A, D). In
order to determine putative differences in self-renewal
upon Nanog-TAT transduction we performed a clonogenicity
assay in which ESCs cultured for 4 passages with Nanog-TAT
with or without LIF, were clonally plated in normal ESC
medium and enriched for Oct4-positve cells by puromycin
selection. Under LIF-withdrawal conditions no single colony
was found in the untreated control cells, whereas a small
percentage of Nanog-TAT-treated cells gave rise to colonies
(1.5 ± 0.2%). LIF-stimulation was more potent resulting in
12.3 ± 0.8% colony formation. However, additional Nanog-TAT
Figure 1 Purified recombinant Nanog-TAT specifically binds to consensus DNA sequence and enhances proliferation of mouse
ESCs. A) Nanog-TAT was subjected to an EMSA employing a specific Nanog consensus DNA sequence (Pan & Pei, 2005). A shift of the
protein–DNA complex is observed. The shift can be prevented by the addition of excess unlabeled DNA (competitor). The binding
reaction containing 100 ng of recombinant protein was subjected to a native PAGE exhibiting 5% (bis)acrylamide. After the gel run
was completed the protein–DNA complexes were transferred onto a membrane and the shift was detected using streptavidin–HRP
conjugates. B–D) ESCs were cultured in the presence of the LIF-inhibitor hLIF-05 (Vernallis et al., 1997) to block LIF signaling and
with or without Nanog-TAT. Cumulative cell numbers at each passage were determined for at least 14 days for Bruce-4 (C57BL/6) (B),
Oct4-GiP (C) and at least 17 days for RF8 (D) ESCs. Cells were splitted at a ratio of 1:4 or 1:8 on day 3, 6, 11 and 14 for (B,C) and 3, 6, 11, 14
and 17 days for (D) when they reached the confluency of around 70–80%. E) Oct4-GiP ESCs cultured in the presence of LIF with or without
Nanog-TAT. Cells were cultured for 2 days and then counted. The relative cell expansion within this time period is presented. Statistical
analysis to calculate p-value was carried out using a two-tailed test; * p value b0.05. Data are means +/− s.e.m. n = 5.
684 M. Peitz et al.treatment induced a further increase in cloning efficiency
(15.5 ± 0.8 %) (Fig. 2E).Nanog-TAT-treated ESCs maintain pluripotency
We next monitored the Oct4 transcriptional activity of Nanog-
TAT-treated cells by flow cytometry analysis employing
the Oct4-GiP ESC line. Oct4-GiP ESCs serve as a straightfor-
ward model system since GFP fluorescence and puromycin
resistance is driven by regulatory sequences of the mouse
Pou5f1 (Oct4) gene and thus the transgene is expressed
only in pluripotent and germline cells (Yeom et al., 1996;
Ying et al., 2002). For standardization, we counter selected
differentiated cells by culturing Oct4-GiP ESCs at least
1 week in the presence of puromycin prior to experiments.
Puromycin-selected Oct4-GiP ESCs exhibit a bright GFP
expression resulting in a sharp peak of GFP-high-expressing
cells (99%) (Fig. 3A, middle). Withdrawal of LIF results in
broadening of the peak and concomitant decrease of GFP-
high-expressing cells to about 60% (Fig. 3A, bottom). After
three passages in the absence of LIF the control cells ceased
to proliferate and eluded further analysis. Nanog-TAT-treatedcells in contrast could be further proliferated and exhibited
a distinct pattern of GFP fluorescence (Fig. 3A, top). Low
passage numbers of Nanog-TAT-treated cells displayed het-
erogeneous GFP-expression containing a modest proportion of
GFP-high-expressing cells (47%). However, after continuous
passaging in the presence of Nanog-TAT the population of GFP-
high-expressing cells constantly increased forming a second
distinct population of cells. After seven passages GFP express-
ing cells reached to almost 90% of all Nanog-TAT-treated cells
(Fig. 3A). Application of both LIF and Nanog-TAT resulted
in a high fluorescence intensity similar to that of puromycin-
selected ESCs (Fig. 3B).
To further characterize the Nanog-TAT-treated ESCs we
analyzed pluripotency-associated markers after seven to
eight passages in the absence of LIF. Immunocytochemical
analysis revealed that Nanog-TAT-treated cells stained
positive for AP activity, SSEA-1 and Oct4 (Fig. 3C) and also
stained positive for other pluripotency-associated markers
Sox2, Rex-1 and FoxD3 (Fig. S3). Cells cultured in the pres-
ence of Nanog-TAT and LIF also stained positive for all the
pluripotency-associated markers (Fig. S3). Next we examined
whether Nanog-TAT-treated cells were still pluripotent by
assaying their ability to differentiate into the three germ
Figure 2 Nanog-TAT sustains pluripotency in ESCs in the absence of LIF. A) Nanog-TAT suppresses spontaneous ESC differentiation
of Bruce-4 (C57BL/6) ESCs. ESCs were cultured on gelatin-coated dishes with 100 nM Nanog-TAT for 3 days in the presence or absence
of LIF as indicated. LIF-withdrawn cultures additionally contained the LIF inhibitor hLIF-05, since LIF agonistic activity occurs upon
spontaneous differentiation in a paracrine manner. Over a 3-day period cells cultured without LIF but in the presence of Nanog-TAT
started to differentiate but still showed colonies with a partially ES-like morphology (black arrowhead). ESCs cultured with control
medium lacking both, LIF and Nanog-TAT, completely differentiated into flat cells forming a monolayer. LIF: leukemia inhibitory
factor, LI: LIF inhibitor; Scale bar: 50 μm. B) After 3 days treatment with 100 nM Nanog-TAT, Bruce-4 (C57BL/6) ESCs were fixed and
stained for AP. In the presence of both, LIF and Nanog-TAT, cultures contained almost exclusively undifferentiated ES-like colonies,
whereas ESCs cultured in the absence of LIF but in the presence of Nanog-TAT contained mixed colonies as well. AP: alkaline
phosphatase; Scale bar: 100 μm. C) A quantification of the morphological scoring of Bruce-4 (C57BL/6) ESC colonies cultured for
5 days in different concentrations of Nanog-TAT in the presence or absence of LIF. For classification see text. D) Nanog-TAT
suppressed spontaneous ESC differentiation of Oct4-GiP ESCs (Ying et al., 2002). ESCs were cultured on gelatin-coated dishes with
Nanog-TAT for 3 passages in the presence or absence of LIF as indicated. LIF-withdrawn cultures contained the LIF inhibitor hLIF-05.
Cells were splitted at a ratio of 1:4 or 1:8 every 2–4 days when they reached the confluency of 70–80%. After 3 passages, Oct4-GiP
ESCs cultured in the absence of LIF and in the presence of 100 nM of Nanog-TAT still exhibit mixed colonies. E) Nanog-TAT treatment
increased clonogenicity of Oct4-GiP ESCs. ESCs were cultured for 4 passages in the presence or absence of LIF and 100 nM Nanog-TAT.
Cells were splitted at a ratio of 1:4 or 1:8 every 2–4 days when they reached the confluency of 70–80%. Cells were then clonally
plated in ESC medium with LIF and puromycin for 6 days and originated colonies were counted. Statistical analysis to calculate
p-value was carried out using a two-tailed test; * p value b0.05; *** p value b0.001. Data are means +/− s.e.m. n = 3.
685layers in vitro. For that, Nanog-TAT-treated ESCs cultured
for 12 passages in the absence of LIF were aggregated to form
EBs. After 2 weeks of culture, EBs were analyzed exhibiting
widespread differentiation as determined by staining against
the germ layer markers α-1-fetoprotein (endoderm), desmin
(mesoderm) and cytokeratin (ectoderm) (Fig. 3D). Moreover
we assessed the capacity of Nanog-TAT-treated cells to induce
teratoma formation. For that, Nanog-TAT cultures kept for
11 passages without LIF and 5 more passages in normal ESC
medium were injected into SCID-beige mice resulting in
teratoma formation displaying various differentiated tissues
(Fig. 3E). Finally we analyzed the developmental potential
of Nanog-TAT-treated cells by blastocyst injection. For that,
cells that had been cultured with Nanog-TAT for 8 passages in
the absence of LIF were expanded in normal ESC medium for 5more passages and subsequently injected into blastocysts. PCR
analysis of offspring revealed presence of the GFP-transgene in
various tissues of the living offspring (data not shown). For
teratoma as well as blastocyst injection we expanded the cells
first in Nanog-TAT for 11 and 8 passages, respectively, in absence
of LIF, and then in normal ESCmedium.We did this for technical
reasons since we observed that Nanog-TAT protein tended to
clog the injection needle yielding overall low cell survival.Nanog-TAT suppresses endoderm specification in ESCs
In order to examinewhether Nanog-TATmaintains pluripotency
autonomously from the JAK/Stat pathway we employed
chemical inhibition to the JAK/Stat signaling pathway
Figure 3 Nanog-TAT sustains pluripotency in ESCs on further expansion in the absence of LIF. A) Flow cytometry analysis of
Oct4-GiP ESCs in response to Nanog-TAT. Even after 7 passages in the absence of LIF, Nanog-TAT induces a proliferating population of
GFP-positive cells (top panel). Untreated cells completely differentiate to non-proliferating cultures within 3 passages, which could
not be further analyzed by flow cytometry (bottom panel). Grey: wildtype Bruce-4 (C57BL/6) ESCs; n. d., not determined. B) Flow
cytometry analysis of Oct4-GiP ESCs cultured for 4 passages in the presence of LIF with (black line) or without Nanog-TAT (dotted line).
Grey, Bruce-4 (C57BL/6) control cells. C) Immunocytochemical analysis of Oct4-GiP ESCs cultured in the absence of LIF with Nanog-TAT
at passage 8. Colonies appeared monolayered and pluripotent state is maintained by Nanog-TAT as judged by staining against
pluripotency-associatedmarkers like Oct4, SSEA-1, alkaline phosphatase (AP). Moreover, native GFP fluorescence yielding from the Oct4
promoter-driven GFP reporter construct, is shown. Scale bar: 50 μM (except AP, 25 μM). D) Immunohistochemical analysis of embryoid
bodies (EBs) derived from Oct4-GiP ESCs that had been cultured for 12 passages in the absence of LIF but presence of Nanog-TAT protein.
Sections of EBs shown stained for markers of all the three germ layers: AFP, α-1-fetoprotein; Desmin; CK, cytokeratin. Scale bar: 200 μm.
E) Histological analysis of a teratoma obtained after injection of Nanog-TAT-treated Oct4-GiP ESCs into SCID-beigemice. Before injection
Nanog-TAT-treated ESCs were cultured in the absence of LIF for 11 passages and expanded in normal ESC medium for further 5 passages.
Cells were splitted at a ratio of 1:4 or 1:8 every 2–4 days when they reached the confluency of 70–80%. Various tissues including primitive
neuroepithelium, cartilage tissue, and adenoid tissue were observed. Scale bar: 200 μm.
686 M. Peitz et al.(Thompson et al., 2002). The JAK inhibitor induced massive
differentiation in untreated control cells whereas in Nanog-
TAT-treated cultures more than 50% of the colonies remained
undifferentiated. Even in the presence of a threefold higher
inhibitor concentration, Nanog-TAT was still able to maintain
undifferentiated colonies (Fig. 4A). To rule out unspecific
stimulation of the JAK/Stat pathway by recombinant Nanog-
TAT preparations we assayed the phosphorylation status of
Stat3. Immunoblots of ESC lysates against phosphorylated
Tyrosine 705 of Stat3 showed no enhanced phosphorylation in
the presence of Nanog-TAT (Fig. 4B).
It has been shown that overexpression of Nanog in ag-
gregated ESCs blocks differentiation into primitive endoderm
(Hamazaki et al., 2004). Thereforeweaskedwhether Nanog-TATinfluences the differentiation potential of ESC aggregates
in a similar manner. To this end, Oct4-GiP ESCs were ag-
gregated and cultured for 4 days in the presence or absence
of Nanog-TAT and LIF, respectively, to form EBs. Nanog-
TAT-treated cultures exhibit less EBs with defined, sharp
borders as compared to the control EBs (Fig. 4C). We assessed
the gene expression patterns of pluripotency markers and
early endodermal lineage specification genes by RT-PCR.
Control ESCs upon EB formation showed reduced expression
of pluripotency markers and upregulation of endodermal
markers (Fig. 4D; (Coronado et al., 2013)). Upon Nanog-TAT
treatment and in the absence of LIF we observed mainte-
nance of pluripotency markers Rex-1, Oct4 as well as Nanog
(Fig. 4D). In contrast, endodermal markers such as GATA6
687and transthyretin were found to be downregulated in Nanog-
TAT-treated cells (Fig. 4D). In the presence of LIF neither
GATA6 nor transthyretin-specific RNA was detected irrespec-
tive of the presence of Nanog-TAT (Fig. 4D). Transcription
of the pluripotency-associated genes Rex-1, Oct4 and Nanog
was efficiently induced by LIF; however, Nanog-TAT induced
a further increase in transcriptional activity of these plu-
ripotency genes (Fig. 4D).Discussion
The robust expression and purification of stable and biologi-
cally active eukaryotic proteins represent a bottleneck of
protein transduction technology (Pan et al., 2010; Patsch
& Edenhofer, 2007; Yang et al., 2011). In this study, we
demonstrate recombinant expression and purification of a
cell-permeant version of biologically active Nanog protein.
Although several studies have reported purification of recom-
binant Nanog from different species including mouse (Jauch
et al., 2008; Loh et al., 2006), human (Ha et al., 2009; YangFigure 4 Nanog-TAT inhibits endodermal differentiation in a Stat3
even in the presence of a JAK inhibitor. Oct4-GiP ESCs were cultured w
at clonal density. After 5 days cells were stained for AP and scored by c
differentiated as described in the text. B) Recombinant Nanog-TAT d
assessed for its phosphorylation status by immunoblotting in response
Nanog-TAT; pY705, Tyrosine 705 phosphorylated Stat3. C) Morphology
the presence or absence of Nanog-TAT and LIF. Scale bar, 200 μm. D) N
ESC cultured in both monolayer and in suspension for 4 days in the pres
ESCs cultured inmonolayer is to demonstrate that the starting populati
did express pluripotency markers and showed no expression of endod
Ng-T, Nanog-TAT; TTR, transthyretin.et al., 2009; Yang et al., 2011), Luxi cattle (Hu et al., 2012)
and chicken (Yu et al., 2013) the biological functionality,
however, remained unclear. Recombinant Nanog proteins have
been reported to bind to a consensus DNA sequence using
EMSA or EMSA-like technique (Ha et al., 2009; Jauch et al.,
2008; Loh et al., 2006; Yang et al., 2009; Yang et al., 2011).
One study employing CPP-fused Nanog protein further reports
that recombinant Nanog could translocate to the nucleus
(Yang et al., 2009); however, no further data was shown to
demonstrate the functionality of the protein.
Our study shows that our purified recombinant mouse
Nanog protein from E. coli is stable at cell culture conditions,
translocates to both cytoplasm and nucleus and is biologically
active. Proof of functionality is based on i) the DNA-binding
ability to a well-described consensus sequence, ii) enhance-
ment of proliferation and iii) supporting self-renewal of
mouse ESCs in the absence of LIF but in the presence of LIF
inhibitor to abrogate residual LIF signaling. DNA binding ability
insufficiently determines the functionality of pluripotency-
associated transcription factors. Yang et al. reported that
although recombinant Oct4 and Sox2 proteins bind to the-independent manner. A) Self-renewal is sustained by Nanog-TAT
ith or without Nanog-TAT and with 0.1 and 0.3 μM of JAK-inhibitor
lassifying into three categories: undifferentiated, mixed and fully
oes not induce Stat3 phosphorylation. Tyrosine 705 of Stat3 was
to Nanog-TAT. L, LIF; 0, without LIF; I, inhibitor hLIF-05; Ng-T,
of aggregated Oct4-GiP ESCs, cultured in suspension for 4 days in
anog-TAT inhibited endodermal specification. RT-PCR analysis of
ence or absence of Nanog-TAT and LIF (see (C)). RT-PCR analysis of
on of ESCs used for aggregate formation under different conditions
ermal differentiation markers investigated. EB, embryoid bodies;
688 M. Peitz et al.consensus DNA sequence, the proteins are not fully biologically
active as they fail to regulate most of the target genes
investigated (Yang et al., 2011). Further, we did not observe
any mixed or undifferentiated colonies on the basis of
morphological analysis in the absence of LIF and Nanog-TAT,
but we did observe mixed colonies upon treatment with
Nanog-TAT and in the absence of LIF which were AP positive.
Surprisingly, we did not observe any undifferentiated colonies
in the latter condition although the translocation of Nanog
into the cells was high. The reason for this could be that the
amount of Nanog protein was not ample enough to generate
undifferentiated colonies but was sufficient to enhance
proliferation and self-renewal of subpopulations in ESCs.
These mixed colonies expressed pluripotency-associated
markers and remained pluripotent in the absence of LIF
when compared to cells cultured in the absence of LIF and
Nanog-TAT. The fact that for technical reasons we had to
culture Nanog-TAT-treated cells prior to teratoma as well
as blastocyst injection in normal ESC medium raises the
possibility of a selective outgrowth of a rare subpopulation
of cells that may be responsible for formation of teratoma
and chimera. Although we cannot rule out, we consider this
a rather unlikely scenario since before that Nanog-TAT-
treated cells were cultured for up to 11 passages in the
absence of LIF and in the presence of LIF inhibitor. As
demonstrated, control cells expanded in the absence of LIF
and Nanog and in the presence of LIF inhibitor could not
maintain their self-renewal and pluripotency characteris-
tics, ceased to proliferate and differentiated within 2-4
passages only. These results suggest that continuous applica-
tion of Nanog-TAT kept the pluripotency network active and
maintained self-renewal as well as pluripotency of these
cells in the absence of LIF. In addition, our data indicates that
Nanog suppresses endoderm differentiation indicating that
Nanog exerts its intracellular function in a Stat3-independent
manner. We found endodermal genes such as GATA6 and
transthyretin downregulated upon Nanog gain-of-function by
protein transduction. Thus, Nanog protein transduction data
presented here is in line with other studies reporting that
Nanog suppresses differentiation of ESCs by inhibiting endo-
dermal specification (Chambers et al., 2003; Darr et al.,
2006; Hamazaki et al., 2004; Mitsui et al., 2003). Our finding
that Nanog-TAT not only increases proliferation but also
clonogenicity of ESCs might build a basis for enhanced
suspension culture as a prerequisite for biomedical applications
(Chen et al., 2012; Singh et al., 2010). In conclusion, our results
readily recapitulate previously published reports employing
conventional genetic Nanog overexpression (Chambers et al.,
2003; Mitsui et al., 2003) to enhance proliferation and self-
renewal and maintenance of pluripotency of ESCs. This
confirms that our recombinant Nanog protein from E. coli is
biologically active and provides an effective model to study
the molecular control of pluripotency by modulating stem
cell properties in target cells by non-genetic means.
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